MEDIAPHARMA S R L has a total of 23 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2010. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and foods and drinks are BICYCLETX LTD, NETRIS PHARMA and BENHEALTH BIOPHARMACEUTIC SHENZHEN CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 6 | |
#2 | WIPO (World Intellectual Property Organization) | 6 | |
#3 | Australia | 3 | |
#4 | Canada | 3 | |
#5 | China | 3 | |
#6 | United States | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Peptides | |
#4 | Special foods | |
#5 | Foods |
# | Name | Total Patents |
---|---|---|
#1 | Iacobelli Stefano | 22 |
#2 | Sala Gianluca | 13 |
#3 | Piccolo Enza | 9 |
#4 | Capone Emily | 8 |
#5 | Piantelli Mauro | 7 |
#6 | Fogliano Vincenzo | 6 |
#7 | Tinari Nicola | 6 |
#8 | Muraro Raffaella | 5 |
#9 | Di Risio Annalisa | 5 |
#10 | Traini Sara | 5 |
Publication | Filing date | Title |
---|---|---|
WO2020099235A1 | Bispecific antibodies directed against human 90k and either endosialin or her3 | |
WO2019197651A1 | Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer | |
EP3202788A1 | Endosialin-binding antibody | |
WO2014187777A1 | Novel inhibitors of pvhl-elongin c binding | |
EP2851080A1 | Tomato powder-based composition | |
EP2630160A1 | Erbb3 binding antibody | |
EP2400983A1 | Use of anti-90k monoclonal antibodies for the prevention and treatment of tumors and metastases thereof |